AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot
Published
Published
New three-year contract in place if UK drugmaker continues to manufacture the jab
Oxford Biomedica have inked a new three-year agreement to make AstraZeneca's COVID-19 vaccine beyond 2022.